Horizon's Poor Primary Care Performance Overshadows River Vision Buy

Horizon's deal to buy River Vision to bolster its orphan product pipeline is cast into the shade by a disappointing first quarter performance for its primary care business.

Star
Horizon Pharma's orphan drug business is in the ascendant

A poor first quarter for Dublin, Ireland-headquartered Horizon Pharma PLC's primary care business leading it to lower its full-year revenue guidance and causing a 35% share price plunge on May 8 has overshadowed its acquisition of River Vision Development Corp., a deal which is expected to boost its fast-growing orphan drug segment, and a strong performance of its orphan drugs portfolio.

The buy allows Horizon to get its hands on River's key pipeline product teprotumumab (RV001) for a rare inflammatory eye...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.